Área salud
Elsevier España
Área salud
Verruga común en tatuaje
Área salud
Área salud
Área salud
Área salud
Eficacia a medio plazo (52 semanas) de tildrakizumab en el tratamiento de la psoriasis moderada a severa: un estudio multicéntrico de práctica clínica
El tildrakizumab es un inhibidor de la interleucina 23 (IL-23) aprobado para el tratamiento de la psoriasis en placas. Sin embargo, existen pocos estudios acerca de su eficacia en práctica clínica. Nuestro objetivo fue analizar […]
Área salud
52-Week Mid-term Efficacy of Tildrakizumab in Moderate-to-severe Psoriasis: A Real-life Multicenter Experience
Tildrakizumab is an IL-23-inhibitor that has been approved to treat plaque psoriasis. However, few reports have become available on its efficacy profile in the real-world. Our objective was to study the mid-term efficacy of tildrakizumab […]
Área salud
Standard and Expanded Series Patch Testing Update by the Spanish Contact Dermatitis and Skin Allergy Research Group (GEIDAC)
After the meeting held by the Spanish Contact Dermatitis and Skin Allergy Research Group (GEIDAC) back in October 2021, changes were suggested to the Spanish Standard Series patch testing. Hydroxyethyl methacrylate (2% pet.), textile dye […]